The company said, “For the full year of 2023, the Company reiterated its revenue guidance to be in the range of $148.0 million to $151.0 million, representing growth of 21% to 23% over 2022 revenue. The Company reiterated its expectations for annual set deployments of approximately $25.0 million and $3.0 million to $4.0 million of adjusted EBITDA for the full year of 2023.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results
- Is KIDS a Buy, Before Earnings?
- OrthoPediatrics Corp. to Report Second Quarter 2023 Financial Results on August 1, 2023
- OrthoPediatrics launches, first case using GIRO Growth Modulation System
- OrthoPediatrics Corp. Announces the Launch and First Case Using the GIRO™ Growth Modulation System